Home / Psoriasis / A Study to Assess Efficacy and Safety of Filgotinib in Active Psoriatic Arthritis (EQUATOR)

A Study to Assess Efficacy and Safety of Filgotinib in Active Psoriatic Arthritis (EQUATOR)

  Purpose

This is a multicenter, Phase 2, double-blind, placebo-controlled study in subjects with moderately to severely active Psoriatic Arthritis (PsA) who have an inadequate response or are intolerant to conventional disease-modifying therapy. A total of approximately 124 subjects will be randomized to one of 2 treatment arms in a 1:1 ratio: oral filgotinib tablets q.d. or matching placebo tablets q.d. The Screening visit will occur within 28 days before study drug administration. At Day 1 (Baseline), eligible subjects will be randomized to treatment for a duration of 16 weeks. The study is concluded with a Follow-up period lasting until 4 weeks after the last dose. Consequently, each subject will stay in the study for a maximum of 24 weeks (from Screening visit to Follow-up visit).

Condition Intervention Phase
Psoriatic Arthritis Drug: filgotinib Drug: Placebo Oral Tablet Phase 2

Study Type: Interventional
Study Design:Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title:A Randomized, Double-blind, Placebo-controlled, Multicenter, Phase II Study to Assess the Efficacy and Safety of Filgotinib Administered for 16 Weeks to Subjects With Moderately to Severely Active Psoriatic Arthritis

Resource links provided by NLM:

Further study details as provided by Galapagos NV:

Primary Outcome Measures:

  • Percentage of subjects who have reached ACR20 response as compared to placebo [ Time Frame: Week 16 ]
    To assess the effect of filogotinib on PsA as assessed by ACR20 in PsA patients

Secondary Outcome Measures:

  • Assessment of minimal disease activity (MDA) in filgotinib treated subjects as compared to placebo [ Time Frame: At each visit from screening until the final follow up visit (week 20) ]
    To assess the effect of filogotinib on MDA in PsA patients

  • Percentage of subjects who have reached ACR50 response as compared to placebo [ Time Frame: At each visit from screening until the final follow up visit (week 20) ]
    To assess the effect of filogotinib on PsA as assessed by ACR50 in PsA patients

  • Percentage of subjects who have reached ACR70 response as compared to placebo [ Time Frame: At each visit from screening until the final follow up visit (week 20) ]
    To assess the effect of filogotinib on PsA as assessed by ACR70 in PsA patients

  • Percentage of subjects achieving DAS28(CRP) score as compared to placebo [ Time Frame: At each visit from screening until the final follow up visit (week 20) ]
    To assess the effect of filogotinib on PsA as assessed by DAS28 (CRP) in PsA patients

  • Percentage of subjects achieving SDAI response as compared to placebo [ Time Frame: At each visit from screening until the final follow up visit (week 20) ]
    To assess the effect of filogotinib on PsA as assessed by SDAI response in PsA patients

  • Percentage of subjects achieving CDAI response as compared to placebo [ Time Frame: At each visit from screening until the final follow up visit (week 20) ]
    To assess the effect of filgotinib on PsA as assessed by CDAI response in PsA patients

  • Percentage of subjects achieving EULAR response as compared to placebo [ Time Frame: At each visit from screening until the final follow up visit (week 20) ]
    To assess the effect of filogotinib on PsA as assessed by EULAR response in PsA patients

  • Assessment of psoriatic arthritis response criteria (PsARC) as compared to placebo [ Time Frame: At each visit from screening until the final follow up visit (week 20) ]
    To assess the effect of filogotinib on PsARC in PsA patients

  • Assessment of physician’s and patient’s global assessment of disease activity as compared to placebo [ Time Frame: At each visit from screening until the final follow up visit (week 20) ]
    To assess the effect of filogotinib on physician’s and patient’s global assessment of disease activity in PsA patients

  • Assessment of patient’s global assessment of PsA pain intensity in filgotinib treated subjects as compared to placebo [ Time Frame: At each visit from screening until the final follow up visit (week 20) ]
    To assess the effect of filogotinib on on PsA pain intensity in PsA patients

  • Assessment of joints for tenderness (68) and swelling (66) in filgotinib treated subjects as compared to placebo [ Time Frame: At each visit from screening until the final follow up visit (week 20) ]
    To assess the effect of filgotinib on joint tenderness and swelling in PsA patients

  • Assessment of CRP in filgotinib treated subjects as compared to placebo [ Time Frame: At each visit from screening until the final follow up visit (week 20) ]
    To assess the effect of filogotinib on CRP in PsA patients

  • Psoriasis as assessed by PASI in filgotinib treated subjects as compared to placebo [ Time Frame: At each visit from screening until the final follow up visit (week 20) ]
    To assess the effect of filgotinib on PASI in PsA patients

  • Psoriasis as assessed by PASI50 in filgotinib treated subjects as compared to placebo [ Time Frame: At each visit from screening until the final follow up visit (week 20) ]
    To assess the effect of filgotinib on PASI50 in PsA patients

  • Psoriasis as assessed by PASI75 in filgotinib treated subjects as compared to placebo [ Time Frame: At each visit from screening until the final follow up visit (week 20) ]
    To assess the affect of filgotinib on PASI75 in PsA patients

  • Psoriasis as assessed by PASI90 in filgotinib treated subjects as compared to placebo [ Time Frame: At each visit from screening until the final follow up visit (week 20) ]
    To assess the affect of filgotinib on PASI90 in PsA patients

  • Psoriasis as assessed by PASI100 in filgotinib treated subjects as compared to placebo [ Time Frame: At each visit from screening until the final follow up visit (week 20) ]
    To assess the affect of filgotinib on PASI100 in PsA patients

  • Physician’s and patient’s global assessment of psoriasis in filgotinib treated subjects as compared to placebo [ Time Frame: At each visit from screening until the final follow up visit (week 20) ]
    To assess the affect of filgotinib on Physician’s and patient’s global assessment of psoriasis in PsA patients

  • Assessment of mNAPSI in filgotinib treated subjects as compared to placebo [ Time Frame: At each visit from screening until the final follow up visit (week 20) ]
    To assess the effect of filgotinib on mNAPSI in PsA patients

  • Assessment of pruritis NRS in filgotinib treated subjects as compared to placebo [ Time Frame: At each visit from screening until the final follow up visit (week 20) ]
    To assess the effect of filgotinib on NRS in PsA patients

  • Enthesitis as assessed by SPARCC enthesitis index in filgotinib treated subjects as compared to placebo [ Time Frame: At each visit from screening until the final follow up visit (week 20) ]
    To assess the effect of filgotinib on SPARCC enthesitis index in PsA patients

  • Dactilytis as assessed by LDI in filgotinib treated subjects as compared to placebo [ Time Frame: At each visit from screening until the final follow up visit (week 20) ]
    To assess the effect of filgotinib on Dactilytis in PsA patients

  • Physical function as assessed by HAQ-DI in filgotinib treated subjects as compared to placebo [ Time Frame: At each visit from screening until the final follow up visit (week 20) ]
    To assess the effect of filgotinib on physical function in PsA patients

  • FACIT-Fatigue scale in filgotinib treated subjects as compared to placebo [ Time Frame: At each visit from screening until the final follow up visit (week 20) ]
    To assess the effect of filgotinib on FACIT-Fatigue scale in PsA patients

  • Assessment of SF-36 in filgotinib treated subjects as compared to placebo [ Time Frame: At each visit from screening until the final follow up visit (week 20) ]
    To assess the effect of filgotinib on SF-36 in PsA patients

  • Assessment of Psoriatic Arthritis Impact of Disease Questionnaire (PsAID) in filgotinib treated subjects as compared to placebo [ Time Frame: At each visit from screening until the final follow up visit (week 20) ]
    To assess the effect of filgotinib on PsAID in PsA patients

  • Difference between the number of filgotinib treated subjects and placebo subjects in the number of adverse events [ Time Frame: From screening until the final follow up visit (week 20) ]
    To evaluation safety and tolerability of filgotinib in PsA patients

  • Difference between the number of filgotinib treated subjects and placebo subjects with abnormal clinical laboratory evaluations [ Time Frame: From screening until the final follow up visit (week 20) ]
    To evaluation safety and tolerability of filgotinib in PsA patients

  • Difference between the number of filgotinib treated subjects and placebo subjects with abnormal vital signs [ Time Frame: From screening until the final follow up visit (week 20) ]
    To evaluation safety and tolerability of filgotinib in PsA patients

  • Difference between the number of filgotinib treated subjects and placebo subjects with abnormal physical examination [ Time Frame: From screening until the final follow up visit (week 20) ]
    To evaluation safety and tolerability of filgotinib in PsA patients

  • Difference between the number of filgotinib treated subjects and placebo subjects with abnormal ECG [ Time Frame: From screening until the final follow up visit (week 20) ]
    To evaluation safety and tolerability of filgotinib in PsA patients

  • Difference between the number of filgotinib treated subjects and placebo subjects with abnormal radiographic assessment [ Time Frame: From screening until the final follow up visit (week 20) ]
    To evaluation safety and tolerability of filgotinib in PsA patients

Estimated Enrollment:124
Actual Study Start Date:March 9, 2017
Estimated Study Completion Date:June 2018
Estimated Primary Completion Date:June 2018 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: filgotinib Drug: filgotinib

one filgotinib oral tablet q.d.
Placebo Comparator: placebo Drug: Placebo Oral Tablet

one placebo oral tablet q.d.

About

Check Also

Risankizumab Versus Secukinumab for Subjects With Moderate to Severe Plaque Psoriasis

Study Description Go to  Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts …

Leave a Reply

Your email address will not be published. Required fields are marked *